2. Isotope-Labeled Compounds
  3. Research Area
  4. Stable Isotope-Labeled Inhibitors

Stable Isotope-Labeled Inhibitors

Stable isotope-labeled inhibitors: one or more atoms are replaced by stable isotopic atoms in the molecular structure of the inhibitor, such as 1H, 12C, 14N, and 16O substituted by D(2H), 13C, 15N, and 17O & 18O respectively. Due to the specificity of stable isotope atoms, they can be used for in vivo and in vitro absorption, distribution, metabolism, and excretion (ADME) studies, etc. By introducing stable isotope-labeled inhibitors, it becomes possible to trace precise metabolic pathways and metabolites within organisms. This valuable information provides a foundation for studying synthetic biology, understanding disease pathogenesis, and unraveling the mechanisms of drug actions [1][2][3].

 

References:

[1] J Labelled Comp Radiopharm. 2014 May 15;57(5):350-7.

[2] Metabolomics and Isotope Tracing. Cell. 2018 May 3;173(4):822-837.

[3] Arch Biochem Biophys. 2017 Aug 15;628:123-131.

Stable Isotope-Labeled Inhibitors (3130):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10201S
    Sorafenib-d3 1130115-44-4 99.57%
    Sorafenib-d3 (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Sorafenib-d<sub>3</sub>
  • HY-19939S
    VX-984 1476074-39-1 98.86%
    VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium.
    VX-984
  • HY-131968
    BMS-986202 1771691-34-9 99.92%
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 value of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium.
    BMS-986202
  • HY-100807S
    Quinolinic acid-d3 138946-42-6 99.85%
    Quinolinic acid-d3 is the deuterium labeled Quinolinic acid. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction[1][2].
    Quinolinic acid-d<sub>3</sub>
  • HY-108872S
    Water-18O 14314-42-2 99.99%
    Water-18O is the 18O-labeled Water[1].
    Water-<sup>18</sup>O
  • HY-B1462S1
    Chlorzoxazone-13C 616865-28-2
    Chlorzoxazone-13C is the 13C labeled Chlorzoxazone[1]. Chlorzoxazone is a centrally acting muscle relaxant used to treat muscle spasm and the resulting pain or discomfort[2].
    Chlorzoxazone-<sup>13</sup>C
  • HY-101410S
    SDMA-d6 1331888-08-4 99.03%
    SDMA-d6 is the deuterium labeled SDMA. SDMA (Symmetric dimethylarginine) is an endogenous inhibitor of nitric oxide (NO) synthase activity[1][2].
    SDMA-d<sub>6</sub>
  • HY-B0617S
    S-Adenosyl-L-methionine-d3 68684-40-2 98.05%
    S-Adenosyl-L-methionine-d3 is the deuterated product of S-Adenosyl-L-methionine. S-Adenosyl-L-methionine is endogenously produced from methionine and ATP through the action of methionine adenosyltransferase and is an important orally active methyl donor.
    S-Adenosyl-L-methionine-d<sub>3</sub>
  • HY-D0843S
    N-Ethylmaleimide-d5 360768-37-2 99.49%
    N-Ethylmaleimide-d5 is the deuterium labeled N-Ethylmaleimide. N-Ethylmaleimide (NEM), a reagent that alkylates free sulfhydryl groups, is a cysteine protease inhibitor[1]. N-ethylmaleimide specific inhibits phosphate transport in mitochondria[2]. N-Ethylmaleimide is also a deubiquitinating enzyme inhibitor[3].
    N-Ethylmaleimide-d<sub>5</sub>
  • HY-78131S
    Ibuprofen-d3 121662-14-4 99.18%
    Ibuprofen-d3 is a deuterium labeled Ibuprofen. Ibuprofen is a COX-1 and COX-2 inhibitor with IC50s of 13 μM and 370 μM[1].
    Ibuprofen-d<sub>3</sub>
  • HY-100806S
    Kynurenic acid-d5 350820-13-2 98.35%
    Kynurenic acid-d5 is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8[1][2].
    Kynurenic acid-d<sub>5</sub>
  • HY-15531S
    Venetoclax-d8 1257051-06-1 99.76%
    Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy[1][2][3].
    Venetoclax-d<sub>8</sub>
  • HY-13704S
    SN-38-d3 718612-49-8 99.07%
    SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].
    SN-38-d<sub>3</sub>
  • HY-145119AS
    Mindeudesivir hydrobromide 2779498-79-0 99.46%
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
    Mindeudesivir hydrobromide
  • HY-N0390S
    L-Glutamine-15N 80143-57-3 ≥98.0%
    L-Glutamine-15N is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
    L-Glutamine-<sup>15</sup>N
  • HY-10219S
    Rapamycin-d3 392711-19-2
    Rapamycin-d3 is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC50of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].
    Rapamycin-d<sub>3</sub>
  • HY-15550S
    4'-Hydroxy diclofenac-d4 254762-27-1 98.92%
    4'-Hydroxy diclofenac-d4 is the deuterium labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties[1][2].
    4'-Hydroxy diclofenac-d<sub>4</sub>
  • HY-110228
    Metformin-d6 hydrochloride 1185166-01-1 98.79%
    Metformin-d6 (hydrochloride)e is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy[1].
    Metformin-d<sub>6</sub> hydrochloride
  • HY-16297AS
    Abemaciclib-d8 2088650-53-5 99.57%
    Abemaciclib-d8 is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
    Abemaciclib-d<sub>8</sub>
  • HY-66005S
    Acetaminophen-d4 64315-36-2 99.38%
    Acetaminophen-d4 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent[1][2][3]. Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor[4].
    Acetaminophen-d<sub>4</sub>